Treatments involving glutaredoxins and similar agents

Abstract

The present invention generally relates to treatments involving glutaredoxins. In one aspect, systems and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, airway inflammation or asthma. In some embodiments, a glutaredoxin may be used to treat a subject. Also provided in certain aspects of the present invention are kits for therapies involving glutaredoxins, methods for promoting such therapies, and the like.

What is claimed is: 
     
         1 - 26 . (canceled) 
     
     
         27 . A method of treating cancer comprising administering to a subject having cancer an effective amount of glutaredoxin to treat the cancer. 
     
     
         28 - 34 . (canceled) 
     
     
         35 . A method, comprising:
 administering, to a subject having or being at risk for a condition characterized by oxidative stress, a composition comprising glutaredoxin,   wherein the glutaredoxin is GRX1, GRX2, GRX5 or a modified version thereof.   
     
     
         36 . The method of  claim 35 , wherein the modified version of GRX1, GRX2, or GRX5 comprises an inactivated caspase cleavage site. 
     
     
         37 . The method of  claim 35 , wherein the modified version of GRX1 has a homology of greater than 90% with unmodified GRX1. 
     
     
         38 . The method of  claim 35 , wherein the glutaredoxin active site comprises Cys-Pro-Tyr-Cys, Cys-Ser-Tyr-Cys or Cys-Gly-Phe-Ser. 
     
     
         39 . The method of  claim 35 , wherein the glutaredoxin is a human glutaredoxin. 
     
     
         40 . The method of  claim 35 , further comprising a pharmaceutically acceptable carrier. 
     
     
         41 . The method of  claim 40 , wherein the pharmaceutically acceptable carrier is a carrier for pulmonary delivery. 
     
     
         42 . The method of  claim 35 , wherein the glutaredoxin is administered by pulmonary delivery. 
     
     
         43 . The method of  claim 35 , further comprising administering an additional therapeutic compound. 
     
     
         44 . The method of  claim 43 , wherein the additional therapeutic compound is a thioredoxin. 
     
     
         45 - 46 . (canceled) 
     
     
         47 . A kit comprising a container housing GRX1, GRX2, GRX5 or a modified version thereof and instructions for administering components in the kit to a subject having or being at risk for a condition characterized by oxidative stress. 
     
     
         48 . The kit of  claim 47 , further comprising a container housing a pharmaceutical preparation diluent. 
     
     
         49 . The composition of  claim 27 , wherein the glutaredoxin is GRX1. 
     
     
         50 . The composition of  claim 27 , wherein the glutaredoxin has a homology of greater than 90% with GRX1. 
     
     
         51 . The composition of  claim 27 , wherein the glutaredoxin active site comprises Cys-Pro-Tyr-Cys, Cys-Ser-Tyr-Cys or Cys-Gly-Phe-Ser. 
     
     
         52 . The composition of  claim 27 , wherein the glutaredoxin is a human glutaredoxin. 
     
     
         53 . The composition of  claim 27 , further comprising a pharmaceutically acceptable carrier. 
     
     
         54 . The composition of  claim 27 , further comprising an additional therapeutic compound. 
     
     
         55 . The composition of  claim 54 , wherein the additional therapeutic compound is a thioredoxin.